Bloomberg Intelligence Podcast – Episode Summary

Episode: Meta to Spend Tens of Billions of Dollars on AMD Gear, Buy Stock
Date: February 24, 2026
Hosts: Paul Sweeney, Jennifer, Scarlet Fu (various contributors)
Featured Analysts/Guests: Ed Ludlow, Geetha Ranganathan, Michael Shaw, Drew Redding

Episode Overview

This episode dives into several major stories in tech, media, pharma, and retail, including Meta's massive investment in AMD for AI infrastructure, the ongoing M&A drama with Warner Brothers Discovery and Netflix, Novo Nordisk’s price cuts on popular GLP-1 drugs, and Home Depot’s latest earnings performance.

1. Meta’s Multi-Billion Dollar Deal with AMD

Main Discussion (02:08–05:56)

Key Points:

• Meta’s AI Ambitions:
  Meta (Facebook’s parent) has committed to buy AMD chips and computers tailored for AI workloads, starting H2 2026, as part of a multi-year, multi-billion dollar deal.
• Partnership Mechanics:
  AMD receives not just revenue but also warrants to buy 160 million AMD shares—a noteworthy financial structure.
• Industry Context:
  AMD is a “distant number two” behind Nvidia in data center chips, but this deal is a substantial boost.
• Scale and Power Needs:
  The commitment totals six gigawatts of data center capacity—comparable to six nuclear power plants and enough to supply millions of homes.
• Meta’s Overall Spending:
  CEO Mark Zuckerberg is committing $600 billion over five years, emphasizing the high-stakes nature of AI investment.

Notable Quotes:

• "Six gigawatts of capacity is equivalent to the output of six nuclear reactors. It's enough power for several million homes."
  — Paul Sweeney (02:41)
• "[Meta’s] committing to spending about $600 billion over the next five years or more...if they misspend, quote $200 billion here or there, the risk of not spending that money is greater for them."
  — Paul Sweeney paraphrasing Mark Zuckerberg (04:08)
• "You can't even compute it with the human brain. That's kind of what we're talking about."
  — Ed Ludlow, on AI’s power requirements (05:33)

Memorable Moments:

• Speculation on whether the warrants for AMD shares constitute “circular financing.”
• The explanation of why AI infrastructure deals are measured in gigawatts, underscoring the energy intensity and infrastructural challenges.
• Context on Nvidia partnership—Meta is diversifying, not choosing a single supplier.

2. Media M&A: Warner Brothers Discovery, Netflix, Paramount Skydance

Main Discussion (08:56–13:21)

Key Points:

• Warner Brothers Discovery for Sale:
  Netflix’s offer for Warner Brothers Discovery has been accepted, but Paramount Skydance is still vying with a higher bid (> $31/share).
• Shareholder Attitudes:
  Netflix shareholders see the deal as a “nice to have,” not a necessity, mostly fearing overpayment and regulatory complications.
• Strategic Importance:
  For Paramount Skydance, the deal is “must have”—their streaming business is small, and growth prospects are otherwise bleak.
• Possible Alternatives:
  If Paramount loses, merging with Comcast NBC is a theoretical option but fraught with antitrust risk.

Notable Quotes:

• "At this point, I think majority of the investors really view it as a distraction, at least in the near term."
  — Geetha Ranganathan, on Netflix investors (10:40)
• "For Netflix, there is the added complexity of a long regulatory road...a lot of uncertainty at this time, Paul."
  — Geetha Ranganathan (11:00)
• "There is effectively no plan B for Paramount Skydance...organically, the growth prospects look extremely bleak."
  — Geetha Ranganathan (12:24)

Memorable Moments:

• Analysis of streaming market dynamics and the premium Netflix is willing to pay (25x EBITDA).
• Strategic urgency for Paramount markedly contrasted with Netflix’s cautious posture.

3. Pharma Focus: Novo Nordisk's Price Cuts for Ozempic and Wegovy

Main Discussion (16:22–21:56)

Key Points:

• Price Reduction:
  Novo Nordisk plans to slash list prices for Wegovy and Ozempic in the US by 50% to about $675/month.
• Effects of Price Cuts:
  This will mainly benefit patients on high-deductible insurance and copay plans; actual net price impact will be less due to insurer negotiations.
• Competition and Patient Choice:
  Eli Lilly’s “Zepbound” remains preferred by doctors due to superior results, but cost and insurance accessibility drive actual patient choices.
• Future Market Dynamics:
  Oral formulations (vs. injectable) are set to grow in importance, improving access and potentially filling different market niches.
• Next Innovation Wave:
  The next breakthrough may come from “Amlan” (or similar), a GLP-1 alternative promising similar efficacy with better tolerability.

Notable Quotes:

• "50% on the list...bringing down the monthly cost down from 1350 to about 6, $75 per month."
  — Michael Shaw (16:44)
• "Doctors or the ones we've spoken to, you know, prefer Zepbound. In reality, it comes down to essentially cost and whatever the patient can access."
  — Michael Shaw (18:19)
• "As you know, one of the main drawbacks at the moment of GLP-1 therapy is the GI side effects...so Amlan aims to solve that problem."
  — Michael Shaw (20:33)

Memorable Moments:

• Clear explanation of the difference between “list price” and “net price.”
• Outlook for both injectable and oral obesity treatments in the US market.

4. Retail: Home Depot’s Solid Earnings Amid Housing Uncertainty

Main Discussion (24:56–28:51)

Key Points:

• Earnings Recap:
  Home Depot posted a strong quarter, beating same-store sales expectations and maintaining FY guidance; stock up 2.9%.
• Market Context:
  Demand is steady despite weather impacts; long-term growth limited by housing market stagnation and consumer hesitancy.
• Housing Market Impact:
  Lower mortgage rates haven’t yet stimulated significant home buying activity; consumers are cautious, waiting for better deals and more confidence.
• Tariff Impact:
  Home Depot has absorbed most of its tariff-related cost increases (about 3%) through prices, with ongoing supply chain adjustments.
• Competitive Landscape:
  Lowe’s, reporting next, is expected to show relative strength among professional contractor customers, but faces similar headwinds.

Notable Quotes:

• "If you strip out all the weather impacts...they're really growing demand at about a 1% comp range. So their customer has been resilient."
  — Drew Redding (25:22)
• "There's just a lack of urgency among buyers...until we rebuild that confidence, lower rates aren't having much of an impact."
  — Drew Redding (26:11)
• "Home Depot sources about 50% to 60% of the products they sell from North America...they've done well to diversify their supply chain."
  — Drew Redding (27:26)

Memorable Moments:

• Discussion of consumer psychology in the housing market and its ripple effect on home improvement retailers.

Timestamps for Important Segments

• Meta & AMD AI Deal: 02:08 – 05:56
• Media M&A: Warner, Netflix, Paramount: 08:56 – 13:21
• Pharma/Obesity Drugs – Novo & Eli Lilly: 16:22 – 21:56
• Home Depot Earnings/Industry Update: 24:56 – 28:51

Notable, Attributable Quotes

• Meta/AMD Energy Use:
  “Six gigawatts of capacity is equivalent to the output of six nuclear reactors.” — Paul Sweeney (02:41)
  “You can't even compute it with the human brain.” — Ed Ludlow (05:33)
• Netflix M&A Anxiety:
  “At this point, I think majority of the investors really view it as a distraction, at least in the near term.” — Geetha Ranganathan (10:40)
• Pharma Innovation:
  “Amlan aims to solve that problem.” — Michael Shaw (20:33)
• Consumer Sentiment:
  “There's just a lack of urgency among buyers...they're taking more of a wait and see approach.” — Drew Redding (26:11)

Episode Tone & Takeaways

The episode maintains Bloomberg’s analytical, data-driven tone. The hosts and guests mix concise reporting with deeper, thoughtful analysis, focusing on the practical impacts for investors and consumers alike. The episode is particularly rich in context about market forces, industry shifts, and the enormous scale and stakes of the current tech and pharma races.

End of Summary